Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label First-in-human Single Ascending Dose Study to Explore Safety, Tolerability and Efficacy of Subretinal Administration of CPK850 Gene Therapy in Patients With Retinitis Pigmentosa Due to Mutations in the Retinaldehyde Binding Protein 1 (RLBP1) Gene

Trial Profile

An Open-label First-in-human Single Ascending Dose Study to Explore Safety, Tolerability and Efficacy of Subretinal Administration of CPK850 Gene Therapy in Patients With Retinitis Pigmentosa Due to Mutations in the Retinaldehyde Binding Protein 1 (RLBP1) Gene

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CPK-850 (Primary)
  • Indications Retinitis pigmentosa
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 24 Sep 2019 Planned End Date changed from 7 Nov 2025 to 10 Nov 2025.
    • 01 Mar 2019 Planned End Date changed from 5 Sep 2025 to 7 Nov 2025.
    • 01 Mar 2019 Planned primary completion date changed from 5 Sep 2025 to 7 Nov 2025.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top